MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)
MacroGenics investors take some money off the table
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:12AM CST
MGNX: 33.00 (+0.34)
Equities Lead Investor Sentiments: Coverage Initiated on AMETEK, FedEx, MacroGenics, Walgreens and Apple
PR Newswire - Tue Dec 23, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AMETEK (NYSE: AME), FedEx (NYSE: FDX), MacroGenics (NASDAQ: MGNX), Walgreens (NYSE: WAG), and Apple (NASDAQ: AAPL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
MGNX: 33.00 (+0.34), FDX: 176.42 (-0.52), AME: 53.98 (+0.19), AAPL: 112.01 (-0.53), WAG: 76.67 (+0.16)
MacroGenics, J&J make deal
at Investor's Business Daily - Mon Dec 22, 5:30PM CST
Biotech MacroGenics (MGNX) inked a licensing deal worth as much as $700 mil with Janssen Biotech, a Johnson & Johnson (JNJ) unit, which agreed to pay $50 mil upfront for rights to MGD011, an antibody that targets 2 biomarkers associated with...
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)
MacroGenics Partners With J&J; Stock Jumps
at Investor's Business Daily - Mon Dec 22, 11:33AM CST
Biotech MacroGenics (MGNX) cut a licensing deal worth as much as $700 million with Johnson & Johnson's drug-development arm Monday, sending its stock up 11% to a 10-month high above 38 on the stock market today. Johnson & Johnson's (JNJ) unit Janssen...
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)
MacroGenics teams up with Janssen in blood cancer
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:08AM CST
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
GlobeNewswire - Mon Dec 22, 5:00AM CST
-- MacroGenics licenses MGD011 (CD19 x CD3 DART(R)) to Janssen
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)
Is Boston Scientific (BSX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:50PM CST
On Dec 16, 2014, Zacks Investment Research upgraded Boston Scientific Corporation (BSX) to a Zacks Rank #2 (Buy).
MGNX: 33.00 (+0.34), BSX: 13.13 (+0.07), ABAX: 58.48 (+0.22), HSP: 62.60 (-0.07)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
MacroGenics (MGNX) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:27AM CST
MacroGenics (MGNX) Stock: Moving Average Crossover Alert
MGNX: 33.00 (+0.34)
B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal?
Mark Kroenke - Seeking Alpha - Mon Dec 15, 7:43AM CST
Checkpoint inhibitors are a big deal. What started with ipilimumab has now grown into a class of drugs which are being pursued vigorously by nearly every major pharmaceutical company in the world. In this crowded space, it's worth noting that B7-H3...
MGNX: 33.00 (+0.34)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
MacroGenics Announces Presentation of Pre-clinical Data on new DART(r) Candidate MGD011 at 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Sat Dec 06, 7:30PM CST
December 6, 2014 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of pre-clinical data for MGD011, a humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART(R)) protein, at the 56 Annual Meeting of the American Society of Hematology (ASH), taking place in San Francisco, CA. These data demonstrate potent T-cell mediated anti-tumor activity in preclinical models.
MGNX: 33.00 (+0.34)
MacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Wed Dec 03, 6:17AM CST
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Oppenheimer 25 Annual Healthcare Conference in New York. The presentation will take place on Wednesday, December 10, 2014, at 3:20 p.m. Eastern Time.
MGNX: 33.00 (+0.34)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 33.00 (+0.34), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), CTIC: 2.36 (+0.05), GSK: 42.85 (+0.11), VSTM: 8.30 (+0.19), SNTA: 2.63 (+0.02), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), AMBI: 15.60 (+0.26), CELGZ: 3.34 (-0.01), KPTI: 37.78 (+1.28), NVS: 93.91 (+0.66)
Macrogenics (MGNX) Is Strong On High Volume Today
at The Street - Mon Nov 24, 9:04AM CST
Trade-Ideas LLC identified Macrogenics (MGNX) as a strong on high relative volume candidate
MGNX: 33.00 (+0.34)
Will MacroGenics (MGNX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:39AM CST
Will MacroGenics (MGNX) Continue to Surge Higher?
MGNX: 33.00 (+0.34)
MacroGenics (MGNX) in Focus: Stock Rises 7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 7:37AM CST
MacroGenics, Inc. (MGNX) was a big mover last session, as the company saw its shares rise 7% on the day.
MGNX: 33.00 (+0.34), ICUI: 83.38 (+1.63), GWPH: 68.08 (+1.82), OSUR: 10.26 (+0.25)
MacroGenics to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 3:30PM CST
ROCKVILLE, Md., November 12, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Stifel 2014 Healthcare Conference in New York, NY. The presentation will take place on Tuesday, November 18, 2014 at 10:55 a.m. Eastern Time.
MGNX: 33.00 (+0.34)
MacroGenics Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 12:19PM CST
MGNX: 33.00 (+0.34)